Christopher Bunka net worth and biography

Christopher Bunka Biography and Net Worth

Director of Lexaria Bioscience

Chris was the former CEO of Lexaria and has been Chairman of the Board since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience.

Chris is a serial entrepreneur and has been involved in several private and public companies since the late 1980’s. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on some of Lexaria’s pending patents.

What is Christopher Bunka's net worth?: The estimated net worth of Christopher Bunka is at least $65.03 thousand as of July 30th, 2025. Mr. Bunka owns 18,794 shares of Lexaria Bioscience stock worth more than $65,027 as of October 8th. This net worth approximation does not reflect any other investments that Mr. Bunka may own. Learn More about Christopher Bunka's net worth.
How do I contact Christopher Bunka?: The corporate mailing address for Mr. Bunka and other Lexaria Bioscience executives is 100 – 740 McCurdy Road, Kelowna, BC, V1X 2P7. Lexaria Bioscience can also be reached via phone at (250) 765-6424 and via email at [email protected]. Learn More on Christopher Bunka's contact information.
Has Christopher Bunka been buying or selling shares of Lexaria Bioscience?: Christopher Bunka has not been actively trading shares of Lexaria Bioscience during the last ninety days. Most recently, on Wednesday, July 30th, Christopher Bunka bought 793 shares of Lexaria Bioscience stock. The stock was acquired at an average cost of $13.65 per share, with a total value of $10,824.45. Following the completion of the transaction, the director now directly owns 18,794 shares of the company's stock, valued at $256,538.10. Learn More on Christopher Bunka's trading history.

Christopher Bunka Insider Trading History at Lexaria Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/30/2025	Buy	793	$13.65	$10,824.45	18,794
7/29/2025	Buy	1,040	$13.80	$14,352.00	18,000

Christopher Bunka Buying and Selling Activity at Lexaria Bioscience

Lexaria Bioscience Company Overview

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Today's Range

Now: $3.37

$3.32

$3.67

50 Day Range

MA: $6.86

$2.77

$14.15

2 Week Range

Now: $3.37

$2.77

$21.60

Volume

10,378 shs

Average Volume

27,782 shs

Market Capitalization

$7.10 million

P/E Ratio

N/A

Dividend Yield